ER positive/HER2 negative breast cancers that were resistant to short term letrozole neo-adjuvant therapy and remained highly proliferative as measured by Ki67 expression were amplified for 8p11 and 11q13 [35]. This evidence concerns the gene ERBB2 and breast carcinoma.